https://www.biospace.com/article/embattled-cytodyn

Quote:

---

In March 2022, the FDA placed a partial hold on CytoDyn’s HIV program and a full clinical hold on its COVID-19 program in the U.S.

The FDA identified five distinct areas it wanted the company to remediate. CytoDyn has addressed and submitted documentation for all five, Arman said. The regulator then came back in February with a sixth item, for which the company has since submitted documentation. Arman hopes to hear back “in the very near term” about having the hold lifted .

---